TABLE 1.
SNP analysis
| SNPs | Location on chromosome 10 (MBp) | Location within ENTPD1 | Major/minor allele (+) strand | Healthy control subjects (MAF) | Non–DM-ESRD case subjects (MAF) | Type 2 diabetic ESRD case subjects (MAF) | Control vs. non–DM-ESRD (P) | Odds ratio for non–DM-ESRD | Control vs. type 2 diabetic ESRD (P) | Odds ratio for DM-ESRD |
|---|---|---|---|---|---|---|---|---|---|---|
| rs3176894 | 97504449 | Promoter | A/G | * | * | * | * | * | * | * |
| rs12262943 | 97506434 | Intron | T/C | 0.106 | 0.134 | 0.121 | 0.112 | 1.30 (0.94–1.81) | 0.378 | 1.16 (0.84–1.60) |
| rs6584026 | 97530149 | Intron | C/T | 0.270 | 0.325 | 0.303 | 0.027† | 1.30 (1.03–1.65) | 0.157 | 1.18 (0.94–1.48) |
| rs10882665 | 97541718 | Intron | C/A | 0.360 | 0.398 | 0.382 | 0.154 | 1.17 (0.94–1.46) | 0.391 | 1.10 (0.89–1.36) |
| rs6584028 | 97548769 | Intron | T/C | 0.262 | 0.310 | 0.298 | 0.051 | 1.27 (0.99–1.61) | 0.124 | 1.20 (0.95–1.50) |
| rs7093453 | 97561565 | Intron | C/T | 0.096 | 0.085 | 0.088 | 0.484 | 0.88 (0.60–1.27) | 0.599 | 0.91 (0.64–1.30) |
| rs4918972 | 97569211 | Intron | G/A | 0.143 | 0.116 | 0.136 | 0.142 | 0.79 (0.57–1.08) | 0.694 | 0.94 (0.70–1.27) |
| rs10748648 | 97576857 | Intron | T/A | 0.457 | 0.471 | 0.450 | 0.613 | 1.06 (0.85–1.31) | 0.805 | 0.97 (0.79–1.20) |
| rs12763743 | 97582146 | Intron | A/T | 0.077 | 0.097 | 0.051 | 0.192 | 1.29 (0.88–1.89) | 0.041† | 0.64 (0.42–0.99) |
| rs1342790 | 97590529 | Intron | A/G | 0.474 | 0.484 | 0.478 | 0.703 | 0.84 (0.68–1.05) | 0.873 | 0.98 (0.80–1.21) |
| rs3176883 | 97594931 | Intron | T/C | 0.247 | 0.287 | 0.288 | 0.104 | 1.23 (0.96–1.57) | 0.087 | 1.23 (0.97–1.56) |
| rs12244606 | 97596321 | Intron | C/T | 0.068 | 0.092 | 0.084 | 0.094 | 1.40 (0.94–2.08) | 0.239 | 1.26 (0.86–1.87) |
| rs3181123 | 97597065 | Intron | C/T | 0.349 | 0.377 | 0.370 | 0.280 | 1.13 (0.91–1.41) | 0.395 | 1.10 (0.89–1.36) |
| rs3793744 | 97597256 | Exon 7 (V-I) | G/A | 0.043 | 0.050 | 0.029 | 0.600 | 1.15 (0.69–1.92) | 0.146 | 0.66 (0.38–1.16) |
| rs3897983 | 97608187 | Intron | G/A | 0.125 | 0.104 | 0.091 | 0.223 | 0.81 (0.58–1.14) | 0.037† | 0.70 (0.50–0.98) |
| rs3181121 | 97608570 | Intron | T/C | 0.096 | 0.088 | 0.086 | 0.612 | 0.90 (0.63–1.32) | 0.504 | 0.89 (0.62–1.27) |
| rs11598475 | 97611256 | Intron | G/A | 0.132 | 0.119 | 0.135 | 0.448 | 0.88 (0.64–1.22) | 0.897 | 1.02 (0.75–1.38) |
| rs3181118 | 97613366 | Intron | C/T | 0.032 | 0.029 | 0.027 | 0.725 | 0.89 (0.48–1.67) | 0.555 | 0.83 (0.45–1.53) |
Individual SNP results for the association study comparing African American control subjects with type 2 diabetic ESRD and nondiabetoc ESRD. *rs3176894 did not meet quality control criteria.
†P < 0.05 (boldface). When the odds ratio is >1, the minor allele is the risk allele; when the odds ratio is <1, the minor allele is the protective allele. MAF, minor allele frequency.